{"id":"low-bup-nal-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Withdrawal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine acts as a partial agonist at the mu-opioid receptor, providing sufficient opioid activity to prevent withdrawal while having a ceiling effect on respiratory depression. Naloxone is included to discourage intravenous misuse by precipitating withdrawal if injected. The low-dose formulation aims to optimize the risk-benefit profile for opioid use disorder treatment.","oneSentence":"A combination of buprenorphine (partial opioid agonist) and naloxone (opioid antagonist) at reduced doses to treat opioid use disorder with potentially improved safety and tolerability.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:30.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"}]},"trialDetails":[{"nctId":"NCT00710385","phase":"PHASE3","title":"Abuse Liability of Suboxone Versus Subutex","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opioid-related Disorders","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Suboxone"],"phase":"phase_3","status":"active","brandName":"Low Bup/Nal Dose","genericName":"Low Bup/Nal Dose","companyName":"New York State Psychiatric Institute","companyId":"new-york-state-psychiatric-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination of buprenorphine (partial opioid agonist) and naloxone (opioid antagonist) at reduced doses to treat opioid use disorder with potentially improved safety and tolerability. Used for Opioid use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}